-+ 0.00%
-+ 0.00%
-+ 0.00%

ImmunityBio hit with securities class action over ANKTIVA promotion claims

PUBT·04/16/2026 13:01:49
Listen to the news
ImmunityBio hit with securities class action over ANKTIVA promotion claims
  • Securities class action filed against ImmunityBio over alleged misstatements tied to promotion of lead drug ANKTIVA.
  • Complaint targets investors who bought shares between Jan. 19, 2026, and March 24, 2026.
  • Shares fell $1.98, or 21%, to $7.42 on March 24, 2026, following disclosure of an FDA Warning Letter.
  • FDA Warning Letter dated March 13, 2026, cited what agency described as false or misleading promotional communications that overstated ANKTIVA benefits.
  • Lawsuit alleges company concealed limits of ANKTIVA approval for a narrow bladder cancer indication while marketing it as broadly effective against cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604160900PR_NEWS_USPR_____NY35854) on April 16, 2026, and is solely responsible for the information contained therein.